Summary Hepatic arterial floxundine (HAI) in 35 patients with systemic fluorouracilfolinic acid-resistant colorectal liver metastases achieved a 140o partial response and 260o disease stabilization rate. with a median response duration of 7 months from onset of HAI.
Howexer. virtuallv all colorectal lixer metastases become resistant .Adx-anced Colorectal Cancer Meta-analv-sis Project. 1992). and man! patients then seek second-line treatments to prolong disease control.
There are no second-line chemotherapies of proven survival or quality of life benefit in colorectal cancer. Hepatic arterial floxuridine infusion (HAI) in patients with untreated colorectal lixer metastases Piedbois et al. 1996W produces a higher partial response rate 140c%) than with bolus systemic tluorouracilUfolinic acid administration (23cc). Thus. HAI might be a useful secondline treatment in patients >-hose colorectal lixer metastases haxe become resistant to sx stemic fluorouracilUfolinic acid. Response to HAI has been reported in comparatixve studies of sx stemic xs hepatic arterial floxuridine (Kemeny et al. 1987 : Hohn et al. 1989 .
in wxhich patients allo-cated to the sxstemic control arm whose disease failed to respond were then crossed oxver to the hepatic arterial studv arm. As a result. HAI has been recommended for treatment of patients Xx ith sy-stemic chemotherapy-resistant lixer metastases ) Kemenv et al. 1993 (Piedbois et al 1996) may result from fluorouracil-induced up-regulation of enzxmes. such as thymidylate synthase. which modulate the cvtotoxic effect of floxuridine (Jenh et al. 1985) . Although non-fluorinated pyrimidine cvtotoxics. such as the topoisomerase inhibitor irinotecan. are more logical choices for second-line chemotherapy in fluorouracil-resistant colorectal cancer (Rothenburg et al. 1996) . results currently suggest only an 18%/e partial response rate associated xx ith a 1.9%7 incidence of fatal toxicity (Rougier et al. 1997) . A higher response rate (33%) has been reported xxith combined intrahepatic fluorouracil and human interferon c2b. but with grade III/IV toxicitv in 62%=-of patients (Patt et al. 1997 ).
The monthly RSC and HAD qualitx of life (QoL) assessments may hax-e underestimated the extent of the HAI-associated QoL deficit compared wxith the SIP. xxhich suggested a greater QoL abnormalitx. Any QoL deficit is also likely to haxe been underestimated at the terminal stage of disease because most patients did not complete QoL questionnaires during the month before death.
HAI patients in this study receixed intra-arterial dexamethasone after prexious studies (Kemeny et al. 1992 ) reporting reduced toxicity and improx ed response compared wxith floxuridine alone. and this mav hax-e influenced QoL independently of the floxuridine effect. Despite these limitations. QoL instruments sugaested that quality of life xas preserxed in most of the prexiously treated patients receixinc-H-AI. The commonest QoL deficit was depression (Table 1) . xhich is thought to be disease rather than toxicitx related (Earlam et al. 1996 (Earlam et al. . 1997 suggests that extrahepatic disease progressed while HAI slowed growth in the liver. Thus. liver metastasis patients in whom extrahepatic metastases develop slowly are likely to benefit most from HAI.
First-line chemotherapy for colorectal liver metastases should now involve either systemic (Levi et al. 1994; Tournigand et al. 1997) or regional (Piedbois et al. 1996) fluorinated pyrimidine regimens. which are capable of higher response rates than are achieved (Advanced Colorectal Cancer Meta-analysis Project. 1992) with conventional bolus systemic fluorouracil/folinic acid (O'Connell et al. 1989) . Although HAI slowed liver metastasis progression in 40% of patients with systemic fluorouracil-resistant liver metastases in this study. a more effective role is in the firstline treatment of selected (Burke et al. . 1997 ) colorectal liver metastasis patients in whom prolonged survival with sustained QoL (Allen-Mersh et al. 1994 : Earlam et al. 1997 
